Corvus Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupa...
Latest News
6 days ago · seekingalpha.com
Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real ProductCorvus Pharmaceuticals offers a catalyst-rich, fully funded pipeline, highlighted by soquelitinib's potential for durable remission in atopic dermatitis and PTCL. Soquelitinib's post-treatment durability and safety profile differentiate CRVS from competitors, especially as leading OX40 programs have exited the field. CRVS is funded into Q2 2028, with major readouts—including SIERRA-1 and PTCL Phase 3—expected within this runway, reducing near-term financing risk.
7 days ago · seekingalpha.com
Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by soquelitinib's advancing clinical programs in r/r PTCL and autoimmune indications. The phase 3 trial for relapsed/refractory PTCL remains on track, with interim futility analysis in Q1 2027 and topline data expected by year-end 2027. Positive phase 1 AD data and ongoing expansion into HS and asthma, with multiple catalysts, including initial HS data and China AD results expected in 2027.
3 months ago · globenewswire.com
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialData supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma.
3 months ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
3 months ago · marketbeat.com
Corvus Pharmaceuticals Q2 Earnings Call HighlightsCorvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.
5 months ago · fool.com
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business.
6 months ago · seekingalpha.com
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too EarlyCorvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following encouraging but limited Phase 1 AD data. Soquelitinib shows activity in atopic dermatitis, but questions remain on safety, durability, and efficacy in broader populations versus established treatments. My DCF analysis yields a fair value of $10.07/share, implying 16% downside from current levels, with significant future cash needs likely requiring dilution.
6 months ago · fool.com
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next PhaseCorvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
6 months ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call TranscriptCorvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
7 months ago · globenewswire.com
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CRVS